BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22532598)

  • 1. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo.
    Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC
    Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
    Pabla N; Huang S; Mi QS; Daniel R; Dong Z
    J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species.
    Chen HM; Chang FR; Hsieh YC; Cheng YJ; Hsieh KC; Tsai LM; Lin AS; Wu YC; Yuan SS
    Free Radic Biol Med; 2011 May; 50(9):1151-62. PubMed ID: 21256211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
    Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
    Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair.
    Pedram A; Razandi M; Evinger AJ; Lee E; Levin ER
    Mol Biol Cell; 2009 Jul; 20(14):3374-89. PubMed ID: 19477925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.
    Cui B; Johnson SP; Bullock N; Ali-Osman F; Bigner DD; Friedman HS
    Mol Pharmacol; 2009 Jun; 75(6):1356-63. PubMed ID: 19261750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
    Reinhardt HC; Aslanian AS; Lees JA; Yaffe MB
    Cancer Cell; 2007 Feb; 11(2):175-89. PubMed ID: 17292828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
    Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
    Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.
    Xiao G; Kue P; Bhosle R; Bargonetti J
    Cell Cycle; 2015; 14(5):744-54. PubMed ID: 25565400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
    Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irradiation-induced G2/M checkpoint response requires ERK1/2 activation.
    Yan Y; Black CP; Cowan KH
    Oncogene; 2007 Jul; 26(32):4689-98. PubMed ID: 17297454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
    Fokas E; Prevo R; Pollard JR; Reaper PM; Charlton PA; Cornelissen B; Vallis KA; Hammond EM; Olcina MM; Gillies McKenna W; Muschel RJ; Brunner TB
    Cell Death Dis; 2012 Dec; 3(12):e441. PubMed ID: 23222511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
    Jayachandran G; Ueda K; Wang B; Roth JA; Ji L
    PLoS One; 2010 Aug; 5(8):e11994. PubMed ID: 20700484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the ATR- and ATM-dependent checkpoint responses in cell cycle arrest evoked by pierisin-1.
    Shiotani B; Kobayashi M; Watanabe M; Yamamoto K; Sugimura T; Wakabayashi K
    Mol Cancer Res; 2006 Feb; 4(2):125-33. PubMed ID: 16513843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
    Lee HJ; Hwang HI; Jang YJ
    Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.